RESEARCH HIGHLIGHTS

Why children with Down syndrome are more likely to develop leukemia – and how it might be stopped
TFRI-funded researchers in Toronto have uncovered new information on the intricate relationship between the extra copy of chromosome 21 and leukemia, paving the way to potentially prevent this cancer in the future.

Exposure to ambient air pollution is a significant contributor to lung cancer among non-smokers
Researchers from TFRI’s Pan-Can Lung Study team have pinpointed why more non-smokers are developing lung cancer, providing the basis for creating strategies to personalize screening programs for high-risk individuals.

TFRI-funded biobank used to make important findings that could help personalize and improve treatments for ovarian cancers
Twelve years after it first received TFRI funding, COEUR continues to hold value for Canadian researchers, allowing them to make significant findings that could help personalize treatments for patients diagnosed with ovarian cancer.

New study reveals the genes that drive cancer in a subset of patients with medulloblastoma: Q&A with Dr. Patryk Skowron
A new international study led by researchers partly funded by the TFRI has uncovered a number of genes that drive cancer in a subset of patients with medulloblastoma, the most common brain tumour affecting children.

Lymphoma team publishes two papers on diffuse large B-cell lymphoma in major journal
TFRI-funded researchers at BC Cancer in a new study demonstrate that a genomic test known as whole transcriptome sequencing (RNA-seq) is the best available tool to accurately provide risk stratification and therapy selection for patients with acute myeloid leukemia (AML).

Study identifies that all cancers can be classified into two groups based on presence of YAP protein: Q&A with Dr. Rod Brenner
A group of researchers partly funded by the TFRI has found that all cancers can be classified into two distinct groups based on the presence of a protein known as YAP. These two groups – YAPon cancers and YAPoff cancers – were also found to respond to drugs differently.

RNA-seq is the best available tool to personalize treatment for patients with acute myeloid leukemia, study finds
TFRI-funded researchers at BC Cancer in a new study demonstrate that a genomic test known as whole transcriptome sequencing (RNA-seq) is the best available tool to accurately provide risk stratification and therapy selection for patients with acute myeloid leukemia (AML).

TFRI NEWS

Distinguished Toronto Scientist Dr. Jim Woodgett Takes Up Leadership of Terry Fox Research Institute

Terry Fox Run Challenge: Researchers break fundraising record, raise over $123k for research

The TFRI launches open call for white papers for the Marathon of Hope Cancer Centres Network

New study helps understand who will benefit from immunotherapy

Save the date: Upcoming events

Job Search: Executive Director, Marathon of Hope Cancer Centres Network

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.

Links is compiled and circulated quarterly by TFRI to highlight recently published research by our funded investigators. It is produced by TFRI staff. TFRI is either the principal or supporting funder of the research presented here. We hope you enjoyed reading this issue. Please send any questions or feedback to: links@tfri.ca

The TFRI launches open call for white papers for the Marathon of Hope Cancer Centres Network

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.

Previous issues are available online in our E-Newsletter Archive.

Visit www.tfri.ca to learn more about our research investment portfolio.